Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisFRA:VIA -0.80%58 3-Year Share Buyback Ratio is 1.70 as of Jun. 2026. GuruFocus rates FRA:VIA with a GF Score™ of 58/100 and a GF Value™ of €10.18 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 645 Drug Manufacturers companies, Viatris ranks better than 95.81% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Viatris's current 3-Year Share Buyback Ratio was 1.70%.
The historical rank and industry rank for Viatris's 3-Year Share Buyback Ratio or its related term are showing as below:
FRA:VIA'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -33 Med: -1 Max: 7.4
Current: 1.7
During the past 13 years, Viatris's highest 3-Year Share Buyback Ratio was 7.40%. The lowest was -33.00%. And the median was -1.00%.
FRA:VIA's 3-Year Share Buyback Ratio is ranked better than 95.81% of 645
companies
in the Drug Manufacturers industry
Industry Median: -2.1
vs FRA:VIA: 1.70
Viatris (FRA:VIA) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Viatris 3-Year Share Buyback Ratio Related Terms
FRA:VIA vs NBIX, UTHR, ELAN: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Viatris's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 1.70 mean?
Viatris (FRA:VIA) has a 3-Year Share Buyback Ratio of 1.70 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Viatris and its competitors. According to the industry distribution chart, Viatris ranks #27 out of 645 companies in the Drug Manufacturers industry, placing it in the top 4.2%.
Is Viatris' 3-Year Share Buyback Ratio too high?
Viatris' current 3-Year Share Buyback Ratio is 1.70. Based on the distribution chart, Viatris ranks #27 out of 645 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' 3-Year Share Buyback Ratio compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #27 out of 645 companies for 3-Year Share Buyback Ratio. This places Viatris in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Viatris and its competitors. Viatris's current 3-Year Share Buyback Ratio is 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (FRA:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.18, compared to a current price of €14.45 — trading 42% above its estimated fair value. The current 3-Year Share Buyback Ratio is 1.70. Viatris' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Viatris (FRA:VIA), the current 3-Year Share Buyback Ratio is 1.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (FRA:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.45 is trading 42% above its estimated GF Value™ of €10.18.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for FRA:VIA:
3-Year Share Buyback Ratio: 1.70
GF Value™: €10.18 vs. price of €14.45 (42% above fair value)
No single metric tells the full story. See the FRA:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for FRA:VIA
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VIA has been successfully added to your 
